Articles Vol. 65 No. 4 10/06/2024

34. TREATMENT RESULTS OF PEDIATRIC PATIENTS WITH PNEUMONIA USING VANCOMYCIN AND SOME RELATED FACTORS AT NGHE AN OBSTETRICS AND PEDIATRICS HOSPITAL

Bui Anh Son1,2, Nguyen Thi Dieu Thuy3,4
1 Nghe An Obstetrics and Pediatrics Hospital
2 Bệnh viện Sản Nhi Nghệ An
3 Hanoi Medical University
4 Đại học Y Hà Nội
Corresponding author: drsonres@gmail.com
DOI: 10.52163/yhc.v65i4.1223
20 Views
18 Downloads
Keywords
Pneumonia, vancomycin, trough concentration, area under the curve.
Abstract

Objective: To review the treatment results of pediatric pneumonia patients using vancomycin and
find out some its related factors.

Subjects and methods: Descriptive study of 129 pediatric patients were diagnosed with pneumonia
using treatment vancomycin at the Obstetrics and Pediatrics Hospital from April 2023 to March 2014.

Results: The percentage of patients cured and improved after treatment was high, accounted for
58.9% and 28.7%, respectively. The death rate was low (1.6%). The median treatment period was 14
days. The mean initial maintenance vancomycin dose was 59.5 ± 2.3 mg/kg/day with dosing intervals
every 8 hours in most pediatric patients in the study (89.9%). The median duration of vancomycin
treatment was 10 (7-13) days. The rate of achieving the AUC target (400 - 600 mg.h/L) in the first
dosing was 67.4%. Adverse events during vancomycin infusion accounted for 10.3%. Factors
associated with an increased risk of subtherapeutic AUC at first measurement include: age > 24
months, increased renal clearance, and shock.

Conclusion: It is necessary to optimize the initial dose of vancomycin in the population of
pneumonia pediatric patients using vancomycin based on monitoring blood drug concentrations
according to AUC taking into account factors such as age, renal clearance, and shock.

References
[1]
Geberetsadik A, Worku A, Berhane Y, Factors Google Scholar
[2]
associated with acute respiratory infection in Google Scholar
[3]
children under the age of 5 years: evidence from the Google Scholar
[4]
Ethiopia Demographic and Health Survey. Google Scholar
[5]
Pediatric Health, Medicine and Therapeutics. Google Scholar
[6]
;6:9. doi:10.2147/PHMT.S77915 Google Scholar
[7]
Rybak MJ, Le J, Lodise TP et al., Therapeutic Google Scholar
[8]
monitoring of vancomycin for serious Google Scholar
[9]
methicillin-resistant Staphylococcus aureus Google Scholar
[10]
infections: A revised consensus guideline and Google Scholar
[11]
review by the American Society of HealthSystem Pharmacists, the Infectious Diseases Google Scholar
[12]
Society of America, the Pediatric Infectious Google Scholar
[13]
Diseases Society, and the Society of Infectious Google Scholar
[14]
Diseases Pharmacists. Am J Health Syst Pharm. Google Scholar
[15]
;77(11):835-864. doi:10.1093/ajhp/zxaa036 Google Scholar
[16]
Kidney Disease Improving Global Outcomes Google Scholar
[17]
(KDIGO), Summary of Recommendation Google Scholar
[18]
Statements. Kidney International Supplements. Google Scholar
[19]
;2(1):8-12. doi:10.1038/kisup.2012.7 Google Scholar
[20]
Schwartz GJ, Work DF, Measurement and Google Scholar
[21]
estimation of GFR in children and adolescents. Google Scholar
[22]
Clin J Am Soc Nephrol. 2009;4(11):1832-1843. Google Scholar
[23]
doi:10.2215/CJN.01640309 Google Scholar
[24]
Phạm Anh Tuân, Phân tích tình hình sử dụng Google Scholar
[25]
kháng sinh điều trị viêm phổi mắc phải cộng đồng Google Scholar
[26]
cho trẻ em tại Bệnh viện Sản Nhi tỉnh Quảng Google Scholar
[27]
Ninh. Luận văn Dược sỹ chuyên khoa cấp 1, Google Scholar
[28]
Trường Đại học Dược Hà Nội, 2019 Google Scholar
[29]
Trịnh Thị Vân Anh, Triển khai hiệu chỉnh liều Google Scholar
[30]
vancomycin thông qua giám sát nồng độ thuốc Google Scholar
[31]
trong máu theo ước đoán Bayesian tại khoa Nhi Google Scholar
[32]
Bệnh viện Bạch Mai. Luận văn thạc sỹ Dược học, Google Scholar
[33]
Trường Đại học Dược Hà Nội, 2022 Google Scholar
[34]
Le J, Bradley JS, Murray W et al., Improved Google Scholar
[35]
vancomycin dosing in children using area under the Google Scholar
[36]
curve exposure. Pediatr Infect Dis J. 2013;32(4):e155- Google Scholar
[37]
e163. doi:10.1097/INF.0b013e318286378e Google Scholar
[38]
Park SJ, Lim NR, Park HJ et al., Evaluation of risk Google Scholar
[39]
factors for vancomycin-induced nephrotoxicity. Google Scholar
[40]
Int J Clin Pharm. 2018;40(5):1328-1334. Google Scholar
[41]
doi:10.1007/s11096-018-0634-8 Google Scholar
[42]
Kondo M, Nakagawa S, Orii S et al., Association of Google Scholar
[43]
Initial Trough Concentrations of Vancomycin with Google Scholar
[44]
Outcomes in Pediatric Patients with Gram-Positive Google Scholar
[45]
Bacterial Infection. Biol Pharm Bull. 2020;43(10): Google Scholar
[46]
-1468. doi:10.1248/bpb.b19-01003 Google Scholar